血清LRG1表达水平在乳腺癌诊断中的应用OA

Objective:To detect leucine-richalpha-2-glycoprotein 1(LRG1)of breast cancer patients in serum and in cancer tissues,respectively,and to analyze their clinical significance.Method:A total of 86 female patients with breast cancer treated in Mudanjiang Tumor Hospital from June 2021 to March 2022 were selected,86 patients with lobular hyperplasia or fibroma of the breast were selected as the benign group,and 21 healthy volunteers were selected as the control group.Difference of serum LRG1 expression among the three groups were compared,and then their relationship with clinical factors such as patients'age,clinical stage and lymph node metastasis were analyzed.Mean gray value of LRG1 expression was detected by immunohistochemical staining in breast cancer tissues and the adjacent tissues,respectively.Result:Level of serum LRG1 in breast cancer group and benign group was much higher than that in control group,and LRG1 expression in breast cancer group was significantly higher than that in benign group,the differences were significant difference(P<0.05).There was significant difference in serum LRG1 expression in patients with different age(P<0.05).Serum LRG1 expression in patients with stage Ⅰ+Ⅱ was significantly lower than that of patients with stage Ⅲ+Ⅳ,the difference was statistically significant(P<0.05).Serum LRG1 expression in lymph node metastasis group statistically was higher than that of no lymph node metastasis group,the difference was statistically significant(P<0.05).Mean gray value in breast cancer tissues was significantly lower than that in the adjacent tissues,the difference was statistically significant(P<0.05).Conclusion:Serum LRG1 is significantly elevated in serum and cancer tissues of breast cancer patients,and closely related to clinical factors,which can be used as a potential biomarker for diagnosis of breast cancer.